Durlobactam sodium salt

Durlobactam sodium salt is an inhibitor of β-lactamase with IC50 values of 4 nM, 14 nM, and 190 nM for Class A KPC-2, Class C AmpC, and Class D OXA-24, respectively. Durlobactam sodium salt can be used in studies about drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Durlobactam is a novel broad-spectrum intravenous beta-lactamase inhibitor commonly used in combination with beta-lactam antibiotics, particularly Sulbactam. Sulbactam is an intravenous beta-lactam antibiotic with intrinsic antibacterial activity against Acinetobacter baumannii complex (ABC) infections. In May 2023, Sulbactam/Durlobactam (XACDURO®) received FDA approval in the United States for patients aged 18 and older, indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible strains of ABC. This medication is a combination product designed to address infections caused by the Acinetobacter baumannii?Calcoaceticus?Baumannii complex. The use of Durlobactam prevents the degradation of Sulbactam by beta-lactamases produced by ABC, enhancing its efficacy.

1467157-21-6

C8H10N3NaO6S

Durlobactam sodium salt is the sodium salt form of Durlobactam, also known as ETX2514, Duobatan sodium, and Durobatan sodium. It is a beta-lactamase inhibitor with varying degrees of inhibition against beta-lactamases of classes A, C, and D. Durlobactam sodium salt can be used for research on multidrug-resistant Gram-negative bacteria, including Acinetobacter baumannii.

Beta-lactamases are enzymes produced by certain bacteria, categorized into four classes (A, B, C, and D). These enzymes contribute to bacterial multidrug resistance by inactivating beta-lactam antibiotics, such as penicillins, cephalosporins, monobactams, and carbapenems. Beta-lactam antibiotics constitute a widely used class of antibiotics characterized by a common four-membered core structure known as a beta-lactam ring. Beta-lactamases hydrolyze the beta-lactam ring, rendering the antibiotics ineffective and leading to bacterial resistance. Gram-negative bacteria commonly produce beta-lactamases, and clinically relevant organisms include members of the Acinetobacter?Calcoaceticus?Baumannii (ACB) complex. The rapid acquisition of multidrug resistance, encompassing fluoroquinolones, aminoglycosides, cephalosporins, and carbapenems, by the ACB complex limits therapeutic options, posing a significant global public health threat. The development of drugs targeting such bacteria is of crucial clinical importance.

299.24

Microbiology/Virology

0.9701

Gram-negative bacteria study

[Na+].CC1=C[C@@H]2CN([C@@H]1C(N)=O)C(=O)N2OS([O-])(=O)=O

Antibacterial